Feel Therapeutics Announces Study Results of their Proprietary Digital Precision Medicine Platform, Validating Promising Impact on Mental Health Conditions
SAN FRANCISCO, Dec. 7, 2023 /PRNewswire-PRWeb/ -- Feel Therapeutics, the leading digital precision medicine company that brings objective and passive monitoring to reinvent the way we diagnose, manage, and care for mental & behavioral health, recently announced the results of a study on their platform offered as a digital mental health support program for depression and anxiety in populations with attention-deficit/hyperactivity disorder (ADHD). The study demonstrates the potential impact of continuous passive data monitoring on the outcomes of anxiety and depression in populations with chronic conditions. This comes in addition to a previous study published by Feel Therapeutics that demonstrated improvement in outcomes in populations with a primary condition of depression and anxiety.
- Feel Therapeutics, the leading digital precision medicine company that brings objective and passive monitoring to reinvent the way we diagnose, manage, and care for mental & behavioral health, recently announced the results of a study on their platform.
- Digital Precision Medicine for mental health provides an innovative solution to the growing global mental health crisis.
- Feel is leading the way by bringing precision medicine to mental health, starting with the collection of continuous passive and objective data from their proprietary Digital Precision Medicine Platform.
- "Mental and behavioral health is long overdue for its precision medicine revolution," said Haris Tsirmpas, Co-Founder and CTO of Feel Therapeutics.